A monograph on topical tacrolimus (Protopic®);Monographie du tacrolimus topique (Protopic®)

Annales de Dermatologie et de Venereologie

Volumn 130, Issue 2 II, 2003, Pages 290-302

  Lubbe J ^a   Saurat, J H ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; DILTIAZEM; ERYTHROMYCIN; HYDROCORTISONE ACETATE; HYDROCORTISONE BUTYRATE; KETOCONAZOLE; PIMECROLIMUS; RAPAMYCIN; TACROLIMUS;

ATOPIC DERMATITIS; CHICKENPOX; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG PENETRATION; ERYTHEMA; FOLLICULITIS; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; PRURITUS; REVIEW; SKIN INFECTION;

ADMINISTRATION, TOPICAL; ADULT; CHILD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TACROLIMUS;

EID: 0037309379     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, et al. FK506, a novel immunosuppressant isolated from a streptomyces. J Antibiot 1987;XL(9):1249-55.
2. Meingassner J, Stütz A. Immunosuppressive macrolides of the type FK506: a novel class of topical agents for treatment of skin disease. J Invest Dermatol 1992;98:851-5.
3. Lauerma AI, Maibach H, Granlund H, Erkko P, Kartamaa P, Stubb S. Inhibition of contact allergy reactions by topical FK506. Lancet 1992; 340:556.
4. Nagakawa H, Etoh T, Ishibashi Y, Higaki Y, Kawashima M, Torii H, et al. Tacrolimus ointment for atopic dermatitis. Lancet 1994;344:883.
5. Shaw K, Ho A, Raghawan A, Kim J, Jain J, Park J. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci USA 1995;92:11205-9.
6. Wollenberg A, Sharma S, von Bubnoff D, Geiger E, Haberstok J, Bieber T. Topical tacrolimus leads to profound phenotypic and functional alterations of epidermal antigen presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 2001;107:519-25.
7. Panhans-Gross A, Novak N, Kraft S, Bieber T. Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001;107(2):345-52.
8. Sengoku T, Kishi S, Sakuma S, Ohkubo Y, Goto T. FK506 inhibition of histamine release and cytokine production by mast cells and basophils. Int J Immunopharmacol 2000;22:189-201.
9. Eberlein-Konig B, Ruzicka T, Michel G, Przybilla G. Inhibition of in vitro histamine release (HR) from human basophils by the immunosuppressive drug FK506 (abstract 62). J Invest Dermatol 1993;100:446.
10. Kohyama T, Takizawa H, Akiyama N, Sato M, Ito K, Yamamoto K. A potent immunosuppressant FK506 inhibits IL-8 expression in human eosinophils. Mol Cell Biol Res Commun 1999;1:72-7.
11. Trautmann A, Akdis M, Schmid-Grendelmeier P, Disch R, Brocher E, Blaser K, et al. Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. J Allergy Clin Immunol 2001;108:839-46.
12. Reitamo S, Rissanen J, Remitz A, Grandlund H, Erkko P, Elg P, Autio P, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998;111:396-8.
13. Trull A. Therapeutic monitoring of tacrolimus. Ann Clin Biochem 1998;35:167-80.
14. Prograf, in Compendium Suisse des médicaments, J. Morant and H. Ruppaner, Editors. 2002, Documed.
15. Alak A, Cook M, Bekersky I. A highly sensitive enzyme-linked immunosorbent assay for the determination of tacrolimus in atopic dermatitis patients. Ther Drug Monit 1997;19:88-91.
16. Laskow D, Vincenti F, Neylan J, Mendez R, Matas A. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States multicenter FK506 kidney transplantation group. Transplantation 1996;62:900-5.
17. Potts R, Guy R. Predicting skin permeability. Pharm Res 1992;9:662-9.
18. Aungst B. The influence of fatty acids and fatty alcohols on skin permeability, in Dry skin and moisturizers, M. Lodén and H.I. Maibach, Editors. 1999, CRC Press: Boca Raton. pp.299-307.
19. Ruzicka T, Assmann T, Homey B. Tacrolimus-the drug for the turn of the century? Arch Dermatol 1999;135:574-80.
20. Bekersky I, Fitzsimmons W, Tanase A, Maher R, Hodosh E, Lawrence I. Non-clinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol 2001;44:S17-27.
21. Undre N. Pharmacokinetics of tacrolimus ointment: clinical relevance. Fujisawa internal document.
22. Kawashima M, Nagakawa H, Ohtsuki M, Tamaki K, Ishibashi Y. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. Lancet 1996;348:1240-1.
23. Long C, Finlay A. The rule of hand: 4 hand areas= 2 FTU= 1 g. Arch Dermatol 1992;128:1129-30.
24. Ruzicka T, Bieber T, Schöpf E, Rubins A, Dobozy A, Bos JD, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997;337:816-21.
25. Reitamo S, van Leent E, Ho V. Efficacy and safety of tacrolimus ointment compared with hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002;109:539-46.
26. Reitamo S, Wollenberg A, Schöpf E, Perrot J, Marks R, Ruzicka T, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000;136:999-1006.
27. Alaiti S, Kang S, Fiedler V, Ellis C, Spurlin D, Fader D, et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase 1 study in adults and children. J Am Acad Dermatol 1998;38:69-76.
28. Alien A, Siegfried E, Silverman R, Williams M, Elias P, Szabo S, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001;137:747-50.
29. Suga Y, Tsuboi R, Hashimoto Y, Yoshiike T, Ogawa H. A case of ichthyosis linearis circumflexa successfully treated with topical tacrolimus. J Am Acad Dermatol 2000;42:520-2.
30. Reitamo S, Rustin M, Ruzicka T. Efficacy and safety of tacrolimus ointment compared with hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002;109:547-55.
31. Kang S. Tacrolimus ointment for adults with moderate to severe atopic dermatitis: a dose-escalation study. J Invest Dermatol 1998;100:681.
32. Hanifin J. Use of tacrolimus ointment in 3 to 6 years old with atopic dermatitis (AD): dose-escalation study. J Invest Dermatol 1998;110:681.
33. Soter N, Fleischer A, Webster G, Monroe E, Lawrence I, group, T.o.s. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 2001;44 (Supplement) (1):S39-S46.
34. Paller A, Eichenfield L, Leung D, Steward D, Appell M, group T.o.s. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001;44 (Supplement) (1):S47-S57.
35. Boguniewicz M, Fiedler V, Raimer S, Lawrence I, Leung D, Hanifin J. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol 1998;102: 637-44.
36. Kang S, Lucky A, Pariser D, Lawrence I, Hanifin J, group, T.o.s. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001;44 (Supplement) (1):S58-S64.
37. Hanifin J, Ling M, Langley R, Breneman D, Rafal E, group, T.o.s. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, efficacy. J Am Acad Dermatol 2001;44 (Supplement) (1):S28-S38.
38. Scheuplein R, Blank I. Permeability of the skin. Phys Rev 1971;51:702-47.
39. Lübbe J, Pournaras CC, Saurat JH. Eczema herpeticum during treatment of atopic dermatitis with 0.1 p. 100 tacrolimus ointment. Dermatology 2000;201:249-51.
40. o. Aoyama H, Tabata N, Tanaka M, Uesugi Y, Tagami H. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1 p. 100 FK506 ointment. Br J Dermatol 1995;133(3):494-6.
41. Lübbe J. Topical tacrolimus for atopic dermatitis: euphoria and vigilance. Dermatology 2001;203:1-2.
42. Lübbe J, Sanchez-Politta S, Tschanz C, Saurat JH. Adults with atopic dermatitis, herpes simplex, and topical therapy with tacrolimus: what kind of prevention? Arch Dermatol 2003, in print.
43. Pournaras CC, Lübbe J, Saurat JH. Staphylococcal colonization in atopic dermatitis treatment with topical tacrolimus (Fk506). J Invest Dermatol 2000;116:480-1.
44. Remitz A, Kyllönen H, Granlund H, Reitamo S. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol 2001;107(1):196-7.
45. McKhann C. Primary malignancy in patients undergoing immunosuppression for renal transplantation. Transplantation 1969;8:209.
46. Lindelöf B, Sigurgeisson B, Gäbel H, Stern RS. Incidence of skin cancer in 5.356 patients following organ transplantation. British J Dermatol 2000;143:513-9.
47. Jain A, Yee L, Youk A, Marsh G, Reyes J, Zak M, et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998;66(9):1193-200.
48. Karagas M, Cushing G Jr, Greenberg E, Mott L, Spencer S, Nierenberg D. Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer 2001;85:683-6.